27 results
8-K
EX-99.2
STSA
Satsuma Pharmaceuticals Inc
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
, highly innovative and designed to meet the needs of people with migraine Proprietary, advanced dry-powder formulation technology and single-use nasal … -term barriers to competitive entry / generics Broad IP estate, with60 issued and pending patents, reflects innovative nature of STS101 and our drug
8-K
EX-99.2
STSA
Satsuma Pharmaceuticals Inc
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
studied.
Large and growing multi-billion dollar market Summary STS101 (DHE nasal powder) Next steps 10/31/22 cash: $59.4M Developing innovative
8-K
EX-99.1
ljj0j1ttxf6ih8lp
15 Mar 22
Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights
4:40pm
8-K
EX-99.1
c54cj8qahn4 wzg7
9 Nov 21
Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results
5:00pm
8-K
EX-99.1
o1io83kg1nq0vvl0h
25 Mar 21
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
5:02pm
8-K
EX-99.2
3mcqicmlj5hz 8fr4fp4
1 Mar 21
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
12:00am
8-K
EX-99.1
bscbuuaoi
10 Nov 20
Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
4:21pm
8-K
EX-99.1
adkic1om
11 Aug 20
Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
4:10pm
10-K
jbepk3x
10 Mar 20
Annual report
4:20pm